Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

C-MER Medical Holdings Limited
希瑪醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

UPDATE ON PROPOSED REPURCHASE OF SHARES UNDER THE 2024 PROPOSED SHARE REPURCHASE

This announcement is made by C-MER Medical Holdings Limited (the "**Company**") on a voluntary basis.

Reference is made to the annual general meeting (the "**AGM**") of the Company held on 28 May 2024 and the grant by the shareholders of an unconditional mandate to the Directors to repurchase Shares not exceeding 10% of the issued share capital of the Company, which would be valid until the AGM to be held for the year ending 31 December 2024. Reference is also made to the Company's announcement dated 11 July 2024 in relation to the 2024 Proposed Share Repurchase under the 2024 Repurchase Mandate and the 2024 Share Award Scheme Purchase, which would be effective commencing from 11 July 2024 up to the date on which the next AGM of the Company will be held.

Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as used in announcement of the Company on 11 July 2024.

The board (the "**Board**") of directors of the Company has been carefully monitoring the recent share prices of the Company and also its intention to repurchase shares under the 2024 Proposed Share Repurchase. Taking into account the financial performance and the business prospects of the Company, and the Company's financial position as announced in the Company's announcement of its financial results for the six months ended 30 June 2024, the Board announces that they have resolved that, subject to market conditions, the Company will apply up to HK$100 million of its cash to repurchase shares on market from time to time from the date of this announcement for a period of 12 months.

Dr. Lam Shun Chiu Dennis ("**Dr. Lam**"), an executive director of the Company and a controlling shareholder of the Company, has also informed the Board that he (and/or entities controlled by him) may also seek out suitable opportunities in increasing his shareholding in the Company, and any such increases will be conducted strictly in accordance with the applicable regulatory requirements applicable for securities dealings by him.

The Board believes that the 2024 Proposed Share Repurchase and Dr. Lam's intention both signify the Board's and Dr. Lam's confidence in the intrinsic value of the Shares and the business prospects in the Group's businesses for 2024.

However, shareholders and prospective investors of the Company should note that the 2024 Proposed Share Repurchase will be subject to market conditions and will be at the absolute discretion of the Board. There is no assurance implied or given that as to the timing, quantity or prices of the implementation of the 2024 Proposed Share Repurchase. Shareholders and potential investors are therefore advised to exercise caution when dealing in the Shares.

By order of the Board
C-MER Medical Holdings Limited
Dr. LAM Shun Chiu Dennis
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 5 September 2024

As at the date of this announcement, the Board comprises three executive Directors, namely, Dr. LAM Shun Chiu Dennis, Ms. LI Xiaoting and Dr. LEE Yau Wing Vincent; and four independent non-executive Directors, namely, Dr. Rex AUYEUNG Pak-kuen, Mr. MA Andrew Chiu Cheung, Mr. IP Shu Kwan Stephen and Mr. YIN Ke.